BioPulse · ENYour source for biotech & pharma intelligence: cell therapy, gene therapy, AI drug discovery, regulatory updates, and investment trendshttps://biopulse.news/enChina's Biotech Licensing Boom Reaches a New Inflection Pointhttps://biopulse.news/en/posts/china-biotech-licensing-boom-2026/https://biopulse.news/en/posts/china-biotech-licensing-boom-2026/License-out deals from China-based biotechs reached a record $137.7 billion in 2025. With average deal size up 76% and upfront fees doubling, global pharma is treating China's pipeline as essential infrastructure.Mon, 04 May 2026 00:00:00 GMTinvestChinalicensingbiotechADCdeal-makingKIR-CAR T Cells Signal a New Era for Solid Tumor Immunotherapyhttps://biopulse.news/en/posts/kir-car-solid-tumors-aacr-2026/https://biopulse.news/en/posts/kir-car-solid-tumors-aacr-2026/First-in-human data for KIR-CAR therapy show encouraging safety and early efficacy in ovarian cancer, mesothelioma, and cholangiocarcinoma — a milestone for cell therapy in solid tumors.Mon, 04 May 2026 00:00:00 GMTbuildCAR-TKIR-CARsolid tumorscell therapyAACR 2026Pharma M&A Surges Back in 2026 — Here Is What the Data Showshttps://biopulse.news/en/posts/pharma-ma-rebound-2026/https://biopulse.news/en/posts/pharma-ma-rebound-2026/With $116 billion in biopharma deals in 2025 and a record $228.4 billion in global biotech M&A, 2026 is shaping up as a landmark year for deal-making. Big Pharma is spending big — and the drivers go beyond patent cliffs.Mon, 04 May 2026 00:00:00 GMTinvestM&Abiotechpharmadeal-making2026Boehringer's Dual-Action Obesity Drug Clears Phase III — And The Field Is Taking Noticehttps://biopulse.news/en/posts/survodutide-phase3-obesity-2026/https://biopulse.news/en/posts/survodutide-phase3-obesity-2026/A clinically meaningful 16.6% weight loss in 76 weeks puts survodutide squarely in the race for next-generation obesity treatmentsSat, 02 May 2026 00:00:00 GMTbuildObesityGLP-1SurvodutideBoehringer IngelheimPhase IIIMASHZealand Pharma